Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others

Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March

Lexaria Bioscience Corp (NASDAQ:LEXX) () is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company announced Thursday. 

The company’s hypertension program now consists of five planned studies, three of which were previously announced on February 1 (HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1). Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March.

HYPER-H21-1, as well as new additions HYPER-H21-2 and HYPER-H21-3, are randomized, double-blinded human clinical studies that will take place in Europe, the company said. Study design for HYPER-H21-1 is complete, and university hospital and ethics board approvals have been received. Dosing will begin after shipment of the clinical test articles to the clinical site is completed, pending regulatory clearances.

READ: Lexaria Bioscience plots applied R&D course to DehydraTECH CBD hypertension and antiviral studies

HYPER-H21-2 is designed to monitor ambulatory blood pressure during the 24-hour period after dosing, with subjects wearing portable devices that will record blood pressure at 30-minute and 60-minute intervals. Volunteers will receive a 150mg dose of DehydraTECH-CBD or a placebo three times daily. 

The company hopes that the results of this study will help it understand the effectiveness of DehydraTECH-processed CBD as a potential anti-hypertensive agent over a full day of monitoring, which complements the shorter-term monitoring in HYPER-H21-1. Study design for HYPER-H21-2 is complete and university hospital and ethics board approvals are pending.

Continue reading
  17 Hits

Canntab Therapeutics aims to deliver more precise, easy-to-take THC and CBD via its pills

Only company in North America to have developed a product line of hard pills for a variety of cannabinoid and terpenoid blends Holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License and an Industrial Hemp License from Health Canada. Tablets expected to be released this year

() (OTCMKTS:CTABF) is dedicated to the research and development of oral dosage formulations of cannabis.

The company's delivery system treats a variety of ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, immediate-release and bi-layered tablets.

Canntab is the first to offer medical cannabis in pill form and its suite of products continues to grow. The company's goal is to become a global leader of research in, production of and education about hard pill oral dosage therapeutic cannabis.

The tablets are intended to treat disorders including post-traumatic stress disorder and arthritis, and they can also act as a pain management and appetite loss drug for patients undergoing cancer treatments.

Compared to smoking and edibles, Canntab tablets can deliver precision dosing and more stability, all with no taste or smell, the company said.

Continue reading
  25 Hits

After successful raise of 11 million dollars, Lexaria Bioscience spells out R&D program for 2021

Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives.

Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension and they are also looking at DehydraTECH with Antivirals for COVID-19.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  28 Hits

Canntab Therapeutics granted patent for their hard pill proprietary cannabidiol formulations

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the company, which has filed over a dozen patents, has been granted their second in relation to its proprietary cannabidiol formulations around the hard pill format.

Goldstein telling Proactive what this means for the company and he also said the company plans to prove greater bio-availability through a blood level study at a third party Clinical Research Organization that is currently in the planning stages.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  24 Hits

Lexaria Bioscience plots applied R&D course to DehydraTECH CBD hypertension and antiviral studies

The new programs come on the heels of a recently-closed oversubscribed financing worth US$11 million

Lexaria’s prospective business partners expect evidence that demonstrates initial effectiveness of DehydraTECH in improving drug delivery characteristics prior to entering negotiations

Lexaria Bioscience Corp (NASDAQ:LEXX) () announced a pair of R&D programs Monday focused on DehydraTECH utilizing CBD for hypertension and antivirals to treat COVID-19.

The new programs come on the heels of a recently-closed oversubscribed financing worth US$11 million, which the company said has greatly enhanced its ability to conduct applied R&D designed to test the effectiveness of its patented DehydraTECH drug delivery technology across multiple classes of bioactive substances or drugs.

Lexaria’s prospective business partners expect evidence that demonstrates initial effectiveness of DehydraTECH in improving drug delivery characteristics prior to entering negotiations, the company said. As such, the company considers R&D studies to be a vital early step in establishing relationships with industry partners to utilize DehydraTECH in their product lines.

READ: Lexaria Bioscience bolsters board of directors with Al Reese Jr

Continue reading
  23 Hits

Canntab Therapeutics granted Canadian patent for its hard pill cannabidiol formulations

Canntab CEO Larry Latowsky told shareholders that the granting of the patent is another major milestone that confirms the group’s unique offering

Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) announced Monday it has received a patent covering its proprietary cannabidiol formulations in Canada.

The patent, which has a priority date of January 23, 2017, expires in January 2038.

Toronto-based Canntab develops hard pill cannabinoid formulations in multiple doses and timed-release combinations. The company told shareholders it believes hard pill formulations are superior to other standard CBD and THC delivery systems as they allow for customizable and precise dosing.

READ: Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures

Canntab now has patent protection in Canada and the US, according to Canntab’s legal counsel Gavin Bogle of the law firm Magyar, Bogle & O'Hara LLP.

“The allowance of Canntab's patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab's innovative tableting technology and validates the years of research and development the company has conducted,” Bogle said in a statement.

Continue reading
  23 Hits

InnoCan Pharma generates C$1.8M from exercise of 7.6M share purchase warrants and broker warrants since December 1, 2020

CEO Iris Bincovich: 'The exercise of the warrants indicates that investors are confident in InnoCan Pharma'

In other news, following the unexpected rise in sales on Shir Beauty's e-commerce platform, www.shirbeauty.com, InnoCan announced the full return of the website

Corporation () (FSE:IP4) (OTCMKTS:INNPF) announced Thursday that since December 1, 2020, it has received proceeds of about C$1.8M from the exercise of 7.6 million previously issued common share purchase warrants and broker warrants.

"The exercise of the warrants indicates that investors are confident in InnoCan Pharma,” said CEO Iris Bincovich in a statement.

Bincovich added: "Following our important milestones since our IPO in September 2019, and alongside the proceeds received, we have the financial strength allowing us to bring our Derma product line to the market, and to accelerate our CLX and LPT proprietary programs with the Tel Avi and the Hebrew University."

READ: InnoCan Pharma reveals successful production of CBD-loaded liposomes under aseptic conditions

In addition, following the unexpected rise in sales on Shir Beauty's e-commerce platform, www.shirbeauty.com, InnoCan Pharma announced the full return of the website -- after the restock of products.

Continue reading
  23 Hits

Lexaria Bioscience's DehydraTECH drug delivery system can unlock more effective CBD — and may even help fight COVID-19

Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the current focus, but company eyeing massive markets such as nicotine and painkillers Currently working on using DehydraTECH to deliver antiviral drugs and help in the global fight against coronavirus

Lexaria Bioscience Corp () () is a Canadian company with a patented technology that promises to change the way drugs are delivered into the body.

The Kelowna, British Columbia-based company has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

In 2013, Lexaria’s management decided to pivot from oil to cannabis and within a year had acquired the rights to DeydraTECH, which is now the company’s main focus.

Essentially, DehydraTECH allows cannabidiol (CBD) and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, cornflour and other base ingredients which can then be added to foods, drinks and creams.

It also allows drugs and vitamins – in the case of cannabis, CBD – to enter the bloodstream faster than existing drug delivery platforms.

Continue reading
  24 Hits

Innocan Pharma hits major milestone in company development of CLX platform

Innocan Pharma (CSE: INNO- OTC: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has hit a major milestone in the development of CLX Therapy which holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.

Bincovich telling Proactive they have been able to successfully complete a large-scale production of exosomes. The company is still in the development stage of the CLX platform but this step shows part of the path to commercialization.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  19 Hits

InnoCan Pharma reveals successful production of CBD-loaded liposomes under aseptic conditions

It touted the development as a key "milestone” in the production of CBD-loaded liposomes, as it now permits animal studies and at a later date, human clinical studies ─ both of which bring the product closer to market

InnoCan Pharma founder CEO Iris Bincovich said previous studies with mice and rats indicated that "our technology to embed CBD into liposomes, LPT, can possibly extend the timeframe from hours to weeks"

Corporation () (OTCMKTS:INNPF) (FRA:IP4) said Friday that it would carry out a successful manufacturing demonstration of its liposome platform technology (LPT) to produce CBD-loaded liposomes under aseptic conditions with the Hebrew University, in Jerusalem. 

The company touted the development as an “important milestone” in the production of CBD-loaded liposomes, as it now permits animal studies and at a later date, human clinical studies ─ both of which bring the product closer to market. 

“This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan's CBD-loaded LPT in relevant diseases,” said the company. Previous studies demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection. 

READ: InnoCan Pharma unveils its new user-friendly commercial website

The previous study led by Dr Ahuva Cern, a senior researcher in Professor Barenholz’s lab at the Hebrew University found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using LPT. The same findings were also seen in rats, pointed out the company.

Continue reading
  21 Hits

Lexaria Bioscience bolsters board of directors with Al Reese Jr

Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company

"With the new capital and the right amount of capital discipline, Lexaria should have an excellent future," said Reese

Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) () has bolstered its board with the addition of Al Reese Jr. 

Certified accountant Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company, where he arranged transactions totaling more than US$10 billion over two decades. 

READ: Lexaria Bioscience prices $9.6M public offering as shares set to begin trading on the Nasdaq

"Al is also experienced in negotiating technology license agreements with companies in the US and internationally, and the board of directors looks forward to his guidance as Lexaria continues to evolve and pursue its strategic out-licensing business model," said Chris Bunka, CEO and chairman, at Lexaria.

Reese added in the statement: "I’ve been familiar with Lexaria since inception and have seen this team’s determination to develop and commercialize the DehydraTECH TM technology. 

Continue reading
  39 Hits

TEST NEWTEC - NA Proactive news snapshot

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Corporation () (OTCMKTS:INNPF) (FRA:IP4) reported the successful completion of a large-scale production of exosomes as part of its CBD Loaded Exosome (CLX) Therapy project in collaboration with Professor Daniel Offen of Tel Aviv University. The company said it considers CLX to be a new revolutionary, development-stage, cell therapy-based technology, loaded with CBD (cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases, with the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.

. () (FRA:20MP) said it has received approval from the Canadian Intellectual Property Office for the patent filing around its Quicksome technology. The company's patented Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats. The technology is being applied across a variety of vaccine, drug and nutraceutical application.

Inc () (OTCMKTS:MGXRF) (FRA:0E9) said it has elected Charn Deol and Sean Charland to the company’s Board of Directors at Zinc8 Energy’s Annual General and Special Meeting of Shareholders held on December 16, 2020. The company also announced that during the past 12 months a “significant” number of its outstanding warrants were exercised from previous private placements, providing Zinc8 with more than $3 million in gross proceeds.

Alpine 4 Technologies Inc. () said its Quality Circuit Assembly (QCA) subsidiary has already booked $1.5 million in new work with just its electric vehicle (EV) customers for Q1 2021, with more anticipated in the quarter.  The company, a leading operator and owner of small market businesses, noted that QCA completed $1.2 million in projects for these Fortune 500 EV customers in Q4 2020. Alpine 4 said its investment of $1.25 million into a new SMT line and related equipment for QCA has proven to be a fruitful investment.

Continue reading
  40 Hits

InnoCan Pharma announces successful completion of large-scale exosomes production for its CBD-loaded therapy project

The company said its development-stage CBD Loaded Exosome (CLX) Therapy project brings the combination of the cell healing properties of exosomes and the anti-inflammatory properties of CBD to infected lungs

InnoCan Pharma says the achievement may lead to economic large-scale exosome production for the CBD Loaded Exosome (CLX) Therapy

 Corporation () (OTCMKTS:INNPF) (FRA:IP4) reported the successful completion of a large-scale production of exosomes as part of its CBD Loaded Exosome (CLX) Therapy project in collaboration with Professor Daniel Offen of Tel Aviv University.

The company said it considers CLX to be a new revolutionary, development-stage, cell therapy-based technology, loaded with CBD (cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases, with the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. 

 described the product as acting as a “guided missile,” bringing the combination of the cell healing properties of exosomes and the anti-inflammatory properties of CBD to the infected lungs.

“Innocan is now one of a few public companies in the exosome's science field,” CEO Iris Bincovich said in a statement.

Continue reading
  37 Hits

Lexaria BioScience begins trading on the Nasdaq Exchange in the United States

Lexaria BioScience (NASDAQ: LEXX- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive to bring news the company is now trading on the Nasdaq capital markets. That includes an offering with gross proceeds of 9.6 million.

Bunka telling Proactive what has gotten the company to this point and why the move was made, He also talked about what he feels will be a big 2021 for Lexaria.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  35 Hits

Lexaria Bioscience prices $9.6M public offering as shares set to begin trading on the Nasdaq

It intends to use the net proceeds of the offering, which includes a $1.44 million up-size option, for R&D studies, patent and legal costs, and general working capital purposes

Under the scheme, Lexaria is offering 1,828,571 units, with each unit consisting of one share and one warrant to purchase one share at US$5.25 per unit

Lexaria Bioscience Corp (NASDAQ:LEXX) (NASDAQ:LEXXW) () said its common stock and warrants will begin trading Tuesday (today) on the Nasdaq Capital Market under the ticker symbols 'LEXX' and 'LEXXW.'

In addition, the company also announced the pricing of an underwritten public offering that could raise up to about $11 million and intends to use the net proceeds for research and development studies, patent and legal costs associated, and general working capital purposes.

Under the scheme, Lexaria is offering 1,828,571 units, with each unit consisting of one share and one warrant to purchase one share at US$5.25 per unit. The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. 

READ: Lexaria Bioscience orders additional coronavirus studies of antiviral drugs delivered using DehydraTECH

The warrants have an exercise price of $6.58 per share, are immediately exercisable, and will expire five years following the date of issuance. The company also has granted the underwriter H.C. Wainwright & Co a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock.

Continue reading
  60 Hits

Innocan Pharma closes financing while launching new commercial website shop.innocanpharma.com

Innocan Pharma (CSE: INNO- OTCPINK: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has launched a new consumer website for the sale of their products.

The site is shop.innocanpharma.com Bincovich also told Proactive about their recent closing of their financing as they added 2.3 million dollars into the treasury.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  35 Hits

InnoCan Pharma unveils its new user-friendly commercial website

The site will allow consumers to browse smoothly through its premium CBD-infused derma cosmetic product collection

InnoCan Pharma founder CEO Iris Bincovich said this is a 'great opportunity for Innocan to start with B2C operations that will secure a new and sustainable source of income'

Corporation () (OTCMKTS:INNPF) (FRA:IP4) on Tuesday unveiled its new user-friendly commercial web platform shop.innocanpharma.com. 

The company said that through its wholly-owned subsidiary, Limited (InnoCan Israel), it has signed key agreements with top global companies for the fulfillment, logistics, and service of the website. 

The new website offers a user-friendly experience with excellent navigation and functionality, allowing consumers to see full product information.  The online product distribution will be handled by Brandzon Company Limited, a specialist in e-commerce growth and worldwide acceleration. The Brandzon team has a proven sales track record worldwide, with global third-party logistics (3PL) capabilities.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

Continue reading
  33 Hits

Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures

"We are pleased to have closed this offering so quickly and with only a few investors,” Canntab CEO Larry Lotowsky said in a statement

The debentures are convertible at $0.80 per share and bear a two-year maturity date

Canntab Therapeutics Limited () (OTCQB:CTABF) announced Thursday it had closed a non-brokered private placement of convertible debentures to raise up to C$1,575,000.

The biopharmaceutical company, which specializes in manufacturing hard pill cannabinoid formulations, said that the debentures are convertible at $0.80 per share and bear a two-year maturity date.

Canntab has the right to prepay or redeem a portion or the entire principal amount plus any accrued interest with a minimum of 20 days notice prior to the redemption date, as well as the right to force conversion at the conversion price if the volume weighted average trading price exceeds C$1.20 for 15 straight days.

READ: Canntab to launch in Australia and take part in the nation’s largest cannabis research study

The debentures bear an interest rate of 10% per year. Funds raised will go towards working capital, accordignt to a statement.

Continue reading
  35 Hits

Canntab Therapeutics closes C$8 million non-brokered private placement of convertible debentures

"We are pleased to have closed this offering so quickly and with only a few investors,” Canntab CEO Larry Lotowsky said in a statement

The debentures are convertible at $0.80 per share and bear a two-year maturity date

Canntab Therapeutics Limited () (OTCQB:CTABF) announced Thursday it had closed a non-brokered private placement of convertible debentures to raise up to C$1,575,000.

The biopharmaceutical company, which specializes in manufacturing hard pill cannabinoid formulations, said that the debentures are convertible at $0.80 per share and bear a two-year maturity date.

Canntab has the right to prepay or redeem a portion or the entire principal amount plus any accrued interest with a minimum of 20 days notice prior to the redemption date, as well as the right to force conversion at the conversion price if the volume weighted average trading price exceeds C$1.20 for 15 straight days.

READ: Canntab to launch in Australia and take part in the nation’s largest cannabis research study

The debentures bear an interest rate of 10% per year. Funds raised will go towards working capital, accordignt to a statement.

Continue reading
  35 Hits

InnoCan Pharma announces the closing of its C$2.4M private placement

InnoCan said it plans to use the offering proceeds for general working capital and other corporate purposes

InnoCan Pharma says its investors continue to show confidence in the company

Corporation () (OTCMKTS:INNPF) (FRA:IP4) reported it has closed a non-brokered private placement offering of 10,294,800 units of the company, at a price of $0.23 per unit, for total gross proceeds of C$2,367,804. 

InnoCan said it plans to use the offering proceeds for general working capital and other corporate purposes.

“Our investors continue to show confidence in the company,” said Innocan Pharma CEO Iris Bincovich in a statement.

READ: InnoCan Pharma is taking a true pharmaceutical approach to commercializing cannabinoids

She added: “We are delighted to complete this private placement despite the holiday season and the four months hold period that applies to the units stated.”

Continue reading
  49 Hits